The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

The extension of Botox’s use is also good news for AbbVie, which is in the process of acquiring Allergan in a $63 billion deal. The pivotal element of that deal is bolting on Botox’ $3.6 ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...

Whetstone’s doctor also recommended BOTOX for Chronic Migraine, a product of AbbVie, to help reach her treatment goals. “It allowed me to manage my disease,” she says. Both Whetstone and ...